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Invasive disease caused by Salmonella enter-
ica is a major global public health con-
cern. It has two main clinical forms: enteric
fever and invasive nontyphoidal Salmonella
(iNTS) disease. Enteric fever imposes its
highest burden of disease in South and
South-East Asia and is principally caused
by S. Typhi and S. Paratyphi A. Conversely,
iNTS disease is a particular problem in sub-
Saharan Africa where it is a leading cause of
bacteremia (1, 2) and is mainly caused by
S. Typhimurium and S. Enteritidis. As fac-
ultative intracellular bacteria, Salmonellae
persist and multiply within the intracellu-
lar niche in macrophages but they are also
capable of independent cell-free existence
and this enables the spread of the infec-
tion from macrophage to macrophage. The
way the immune system protects against
these two phases of infection differs and
this is key for developing a strategy to
induce protective immunity against Salmo-
nella. Antibodies have an important role
in eliminating extracellular bacteria, while
specific T cells are important for the clear-
ance of intracellular bacteria. The con-
tribution of these two arms of acquired
immunity against Salmonella infections to
protection has been an area of contro-
versy in the past, and their relative impor-
tance is only now emerging. This opinion
piece focuses on the role of antibodies in
protecting against invasive Salmonella dis-
ease, and the application of this to vaccine
development.
Epidemiological investigation, in vitro
studies, animal models and vaccine stud-
ies indicate that antibodies can kill Sal-
monella that are not shielded by residing
inside host cells. Conceptually, Salmonellae
are exposed and therefore vulnerable to
antibodies at distinct points of the invasion
cycle: following initial invasion, when first
entering the circulation, and when tran-
siting from one phagocyte to another via
the blood or extracellular fluids (3). An
important consideration is the time that
these bacteria are exposed to antibodies
and whether this is sufficient for antibody-
induced killing to occur. In vitro kinetic
studies indicate that there is a window
of opportunity of approximately 10 min
before extracellular S. Typhimurium are
killed by antibody and complement, and
this time is sufficient to allow a proportion
of bacteria entering the blood to escape into
the intracellular niche (4).
Candidate vaccine studies in mice,
where immunization is followed by chal-
lenge with live Salmonella, indicate the
importance of antibodies for protec-
tion. Several studies have investigated
experimental conjugate vaccines based on
purified O polysaccharide from Salmonella
(O-antigen; O:4,5 for S. Typhimurium and
O:9 for S. Enteritidis) (5). Unlike intact
lipopolysaccharides, these O-antigens lack
lipid A and so are unable to act as
thymus-independent type 1 (TI-1) anti-
gens. Because of their repeating struc-
ture, they are likely to behave as
thymus-independent type 2 (TI-2) anti-
gens (6, 7) and therefore be capable of
inducing Salmonella-specific antibodies,
but not T cells. If O-antigen is associated
with Salmonella protein, as it is in the intact
bacterium or when present in membrane-
vesicle-preparations, it has the potential to
induce T-dependent B-cell immunity. T-
cell help permits an immune response to
the O-antigen in infants, affinity matura-
tion of the antibody response and results in
more persistent antibody production and
the induction of memory.
Passive transfer studies of antibody
from immune to non-immune animals
have confirmed an important role for anti-
bodies in protecting against Salmonella
in mice. Nevertheless, the protection that
antibody confers in this model depends on
the inherent resistance to Salmonella of the
mouse strain used, the virulence of the Sal-
monella strain, and the design of the chal-
lenge study. Optimal protection against
Salmonella in mice requires a combination
of antibodies and T cells. T cells appear
to be most important for the late clear-
ance of Salmonella infection (8), involv-
ing killing of intracellular bacteria from
the macrophage beds of the spleen and
liver.
There are a several drawbacks to study-
ing Salmonella infections in mice as a
model of disease in humans. These include
the human restriction of S. Typhi and
Paratyphi A, which limits mouse studies
to nontyphoidal serovars. Also, there are
differences in antibody-mediated immu-
nity to Salmonella in mice and men. In
man, antibodies can kill through direct
complement-fixation and opsonophagocy-
tosis, while in mice there appears to be little
complement-mediated killing (9), leaving
opsonophagocytic mechanisms to effect
killing. In man, although there is evidence
regarding the mechanisms of immune pro-
tection from vaccines against typhoid fever,
no vaccine against NTS has progressed
beyond a phase I clinical study. Hence,
inferences regarding the mechanisms of
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immunity to iNTS disease in man come
primarily from immunoepidemiological
studies.
Of the two widely used types of vaccine
against typhoid, Vi capsular polysaccha-
ride (Vi CPS) vaccine, appears to operate
entirely through the induction of protec-
tive antibody (5, 10). Similar to pure O-
antigen, Vi polysaccharide is likely to be
a TI-2 antigen. Despite lack of conjuga-
tion to a protein moiety, and hence lack
of induction of T-cell immunity, the anti-
bodies induced confer 55% 3-year protec-
tion (10, 11). New vaccines, where Vi CPS
is conjugated to carrier proteins, such as
tetanus toxoid, have been licensed recently
for in-country use in India and China.
These vaccines should provide greater pro-
tection than their unconjugated predeces-
sor, albeit through more persistent and
higher affinity Vi antibody production,
rather than eliciting Salmonella-specific T
cells, as the carrier proteins are usually
not Salmonella-derived. The other widely
used vaccine against typhoid is Ty21a, a
live attenuated vaccine capable of induc-
ing T cells as well as antibodies against
Salmonella. Ty21a has a similar reported
(51%) 3-year efficacy against typhoid as
Vi CPS vaccine. Although Ty21a induces
antibodies, none are directed against Vi,
since it lacks Vi expression. The mech-
anisms by which Ty21a confers its pro-
tection are not well understood, but may
include antibodies against the O:9 anti-
gen which S. Typhi shares with S. Enteri-
tidis.
The absence of a licensed vaccine against
NTS means there is neither vaccine effi-
cacy data nor a correlate of protection for
iNTS disease. Consequently, evidence of
the importance of antibodies in protection
against iNTS disease relies on epidemio-
logical evidence, which shows a correla-
tion between fatal systemic iNTS disease
and the period in childhood when natu-
rally acquired antibodies are absent. This
occurs after maternally-transmitted anti-
body has waned and before antibody has
been induced through exposure, with peak
incidence around one year of age (12).
Although typhoid fever and iNTS disease
are caused by bacteria belonging to the
same species, extrapolating mechanisms of
protection from the one disease to the
other is not straightforward. One reason
for this is the Vi capsule of S. Typhi which
is absent from almost all nontyphoidal
serovars of Salmonella. The capsule has
immunomodulatory effects and has been
shown to reduce inflammation (13–15).
Additionally, it is now clear through geno-
typing that although the S. Typhimurium
in sub-Saharan Africa is serologically indis-
tinguishable from strains in the US and
Europe, they belong to a different clade
(16, 17).
Typhoid fever and iNTS disease have
very different clinical manifestations and
may require different approaches in order
to effect protection by vaccination. Dif-
ferences in their associated comorbidities,
in particular, imply that the mechanisms
of immune protection against these two
forms of invasive Salmonella disease are
not the same. HIV-infected individuals are
highly susceptible to iNTS disease, while
this association is not present with typhoid
fever. Epidemiological data from Tanzania
suggest a protective effect of HIV infec-
tion against typhoid, while an association
between malaria and iNTS disease has long
been recognized. Once again, no such link
appears to exist with typhoid. Finally, indi-
viduals with deficiencies of the IL12/23-
IFNγ cytokine axis (TH1 deficiencies) com-
monly present with iNTS disease, but not
typhoid fever.
As discussed above, the acquisition of
antibodies against NTS with age among
African children corresponds to a fall in
the incidence of episodes of iNTS dis-
ease (12), thus supporting a role for anti-
bodies in protection against iNTS disease
among young children. These antibodies
have been shown to induce killing of Sal-
monella by phagocytes (18) and comple-
ment alone (12). More recently, this early
acquisition of antibody-mediated immu-
nity has been shown to correlate with
levels of antibodies to O-antigen (19),
supporting the development of a vaccine
that induces such antibodies in order to
protect young children in Africa against
iNTS disease. Surprisingly, acquisition of
Salmonella-specific T cells coincides with
a peak in age-related iNTS disease inci-
dence in African children (19), but these
T cells could still play a secondary role
in immunity to Salmonella among such
children. Hence, in otherwise immune-
competent children, a vaccine that can
induce antibodies, particularly antibod-
ies to O-antigen, appears likely to protect
against iNTS disease. The early acquisi-
tion of antibodies to O-antigen occurs
even in locations such as USA (20), where
iNTS disease is uncommon, suggesting
either ubiquitous sub-clinical exposure
to NTS or the development of cross-
reactive antibodies from other immune
stimuli.
The reasons why HIV-infected individ-
uals are susceptible to iNTS are more com-
plex. While those with CD4 counts below
200/µl are most susceptible, the relevant
mechanisms are probably more than just a
reduction in CD4+ T cell-afforded protec-
tion. Dysregulation of anti-iNTS antibody-
specific antibody production and cytokine
responses, and increased invasion of Sal-
monella across the gastrointestinal wall also
seem to be contributory, as does CD17+
T cell deficiency (2). Levels of antibod-
ies against Salmonella O-antigen are much
higher in some HIV-infected, compared
with HIV-uninfected individuals and are
associated with a lack of complement-
mediated killing of Salmonella in vitro
(21). Although the clinical significance of
these findings is not entirely clear, we have
recently described a similar occurrence in
a group of patients with bronchiectasis
and chronic Pseudomonas aeruginosa lung
infection. High levels of IgG2 antibodies to
the O-antigen of Pseudomonas are associ-
ated with both impaired in vitro killing of
these bacteria, increased severity of respi-
ratory infections and poor lung function
(22). Nevertheless, anti-O-antigen anti-
bodies are bactericidal at lower concen-
trations (23). Recurrent episodes of iNTS
disease are a common problem among
HIV-infected African adults. Many are
caused by the same isolate of NTS sug-
gesting persistence of Salmonella infection
(24), even after clinical remission. With
likely persistence in the intracellular niche
and the importance of T cells for clearance
of intracellular infection, a vaccine capa-
ble of inducing Salmonella-specific T cells
may be more important in the context of
HIV infection than the immune naivety of
infancy.
Perhaps surprisingly, iNTS disease is
not a common feature in individuals with
primary antibody deficiencies, such as
X-linked agammaglobulinemia or com-
mon variable immunodeficiency, although
Salmonella gastrointestinal disease has
been reported to be a problem in
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cohort studies of such patients (25).
If, as other evidence indicates, anti-
body is key for protection against Sal-
monella, a lack of iNTS disease may
be due to the low prevalence of Sal-
monella infections and absence of the
ST313 invasive S. Typhimurium patho-
var in industrialized settings, where it
is possible to make a diagnosis of anti-
body deficiency. Alternatively, there may
be redundancy in immunity to Salmo-
nella by the time antibody levels wane and
patients with CVID present with recurrent
infections.
On the other hand, the high inci-
dence of NTS granulomata among indi-
viduals with IL12/23-IFNγ cytokine axis
deficiencies shows that antibodies (and
complement) are insufficient alone to pro-
tect against iNTS disease in man. One
series reported Salmonella disease in 43%
of individuals with IL12/23 or IL12/23-
receptor deficiencies (26). This cytokine
axis is important for macrophage activa-
tion and elimination of intracellular bacte-
ria, in particular Salmonella and mycobac-
teria. When tested, these patients have anti-
bodies against Salmonella. Since they do
not succumb to their Salmonella infec-
tions, it is plausible that, while not being
sufficient to clear the macrophage beds
of intracellular Salmonella, antibodies pre-
vent fatal disease. As with HIV infection,
the Salmonella serovars isolated are almost
always nontyphoidal. Since IL12/23-IFNγ
cytokine axis deficiencies affect signaling in
response to Salmonella by innate/innate-
like lymphocytes, including NK cells and
γδ-T cells (27), the occurrence of Salmo-
nella disease does not necessarily imply
the need for Salmonella-specific T cells.
iNTS disease is common among individ-
uals with chronic granulomatous disease
(25) and African children with malaria
(28). In both cases, the phagocyte oxidative
burst mechanism is impaired, suggesting
the requirement for a functioning innate
immune system to protect against iNTS
disease.
In conclusion, vaccine efficacy studies
strongly support a role for antibodies in
protection against typhoid fever. Immu-
noepidemiological studies from Africa
also support the importance of antibody
for protection against fatal iNTS dis-
ease. However, strong clinical associations
with secondary immunodeficiency due to
HIV infection and malaria, and primary
immunodeficiencies of the IL12/23-IFNγ
cytokine axis and chronic granulomatous
disease, suggest that antibody-mediated
immunity against iNTS disease is only fully
effective in the presence of an otherwise
intact immune system. These observations
indicate that bacteria from the same species
(Salmonella enterica) not only cause dif-
ferent diseases, but that different immune
mechanisms protect against these diseases.
This conclusion may be applicable to other
bacterial pathogens. While an antibody-
inducing vaccine against iNTS disease may
protect immunologically naive, but other-
wise immunocompetent young children, it
may be insufficient to protect individuals
with primary and secondary immune defi-
ciencies. Ultimately, efficacy studies with
vaccines against NTS will be required to
understand the importance of antibodies
against iNTS disease. With no such vaccine
currently even in early stage clinical trials,
we are set for a long wait.
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